Treatment of Acute Coronary Syndromes With Otamixaban - TAO


The optimal anticoagulation strategy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is unclear. The current trial sought to compare the safety and efficacy of otamixaban, a novel intravenous factor Xa inhibitor, as compared with unfractionated heparin (UFH) + eptifibatide in these patients.